Compare LYFT Inc (LYFT) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs ResMed Inc. — how do they compare? LYFT Inc trades at $16.15 (market cap $5.90B), while ResMed Inc. trades at $225.92 (market cap $31.78B). The key difference: ResMed Inc. is far larger — about 5.4× LYFT Inc's market cap, and ResMed Inc. pays a 1.17% dividend while LYFT Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 47 Days and ResMed Inc. for 51 Days on average.
| LYFT | RMD | |
|---|---|---|
Market Cap | $5.90B | $31.78B |
Volume | 9,741,129 | 1,128,382 |
Sector | Technology | Health |
52-Week High | $24.57 | $277.88 |
52-Week Low | $12.65 | $182.82 |
Typical Hold Time | 47 Days | 51 Days |
Enterprise Value | $5.37B | $31.14B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft trades at $16.13, up 2.35% on the day, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company reported strong revenue growth to $6.32B in 2025 and a net income of $2.84B, though recent quarterly EPS results have missed expectations. Positive developments include European expansion and a partnership with Sphere, while a $272.5M legal settlement poses a headwind.
The outlook is mixed; low P/E and P/S ratios suggest undervaluation, and analyst consensus targets $18.07, but execution risks and competitive pressures remain. Earnings consistency is key for sustained upside, with the stock offering value if growth momentum continues despite near-term volatility.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
